Asset profile
AZD0120
Cell therapy
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-06-14.
Also in development:Multiple Sclerosis · Phase 1Rheumatoid Arthritis · Phase 1Systemic Lupus Erythematosus · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
201 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 199 same-indication; 77 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD0120: this drug | Phase 3 | Cell therapy | BCMA / CD19 | ||
| ICG318 | Phase 2 | Cell therapy | BCMA / CD19 | ||
| BCMA-CD19 Compound CAR (cCAR) T Cells | Phase 1 | Cell therapy | BCMA / CD19 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) |
…and 186 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (6)
February 2027 (3)
What to watch
What to watch
What to watch
March 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (7)
February 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
January 2029 (1)
What to watch
May 2029 (1)
What to watch
August 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.